Atrys Health S.A. Logo

Atrys Health S.A.

ISIN

ES0105148003

Ticker

ATRY

Sector

Health Care

Sub-Industry

Biotechnology

Country

Spain

Year Founded

2007

About Atrys Health S.A.

Company Description

Atrys Health (BME: ATRY), founded in 2015, is a Spanish multinational that provides precision medical prediction, prevention, diagnosis and treatment services. Pioneer in the fields of telemedicine and state-of-the-art radiation therapy.

Headcount

283,200

Served Area

Worldwide

Headquarters

Calle principe de Vergara, 132
28002, MADRID
Spain

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets 88,691,000.00 180,971,000.00 565,632,000.00 705,281,000.00
Noncurrent Assets 70,663,000.00 143,707,000.00 462,526,000.00 602,176,000.00
Property Plant And Equipment 5,738,000.00 9,843,000.00 29,555,000.00 29,139,000.00
Deferred Tax Assets 5,635,000.00 5,805,000.00 9,279,000.00 8,874,000.00
Current Assets 18,028,000.00 37,264,000.00 103,106,000.00 103,105,000.00
Trade And Other Current Receivables 8,289,000.00 17,012,000.00 54,551,000.00 56,690,000.00
Current Prepaid Expenses 17,000.00 24,000.00 574,000.00 874,000.00
Cash and cash equivalents 17,476,000.00 35,126,000.00 35,126,000.00 34,295,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners 0.00 0.00 3,404,000.00 3,401,000.00
Equity And Liabilities 88,691,000.00 180,971,000.00 565,632,000.00 705,281,000.00
Equity 39,539,000.00 71,380,000.00 273,979,000.00 337,573,000.00
Issued Capital 256,000.00 347,000.00 614,000.00 760,000.00
Share Premium 38,426,000.00 78,079,000.00 315,501,000.00 420,053,000.00
Treasury Shares 148,000.00 54,000.00 475,000.00 750,000.00
Noncontrolling Interests 0.00 0.00 -51,000.00 -57,000.00
Noncurrent Liabilities 39,334,000.00 88,181,000.00 220,151,000.00 267,145,000.00
Noncurrent Provisions 1,966,000.00 15,115,000.00 4,256,000.00 3,819,000.00
Noncurrent Government Grants 5,829,000.00 5,714,000.00 5,752,000.00 6,745,000.00
Deferred Tax Liabilities 1,223,000.00 7,390,000.00 30,706,000.00 44,937,000.00
Other Noncurrent Financial Liabilities 23,591,000.00 47,813,000.00 42,331,000.00 38,140,000.00
Noncurrent Portion Of Noncurrent Loans Received 5,411,000.00 10,077,000.00 104,475,000.00 140,501,000.00
Current Liabilities 9,818,000.00 21,410,000.00 71,502,000.00 100,563,000.00
Current Provisions 1,049,000.00 875,000.00 12,852,000.00 18,074,000.00
Trade And Other Current Payables 1,910,000.00 5,462,000.00 16,041,000.00 24,912,000.00
Current Government Grants 268,000.00 310,000.00 294,000.00 294,000.00
Other Current Financial Liabilities 2,753,000.00 8,838,000.00 7,229,000.00 26,517,000.00
Current Loans Received And Current Portion Of Noncurrent Loans Received 2,167,000.00 3,150,000.00 12,166,000.00 14,363,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 31,396,000.00 121,014,000.00 186,994,000.00
Other Work Performed By Entity And Capitalised 2,412,000.00 2,838,000.00 4,838,000.00
Raw Materials And Consumables Used 9,558,000.00 22,959,000.00 37,319,000.00
Employee Benefits Expense 11,033,000.00 70,472,000.00 91,730,000.00
Depreciation And Amortisation Expense 5,973,000.00 20,788,000.00 30,345,000.00
Profit Loss From Operating Activities -230,000.00 -15,014,000.00 -11,117,000.00
Finance Income 210,000.00 1,848,000.00 2,906,000.00
Finance Costs 4,419,000.00 9,969,000.00 15,218,000.00
Profit Loss Before Tax -5,381,000.00 -24,882,000.00 -24,693,000.00
Income Tax Expense Continuing Operations 167,000.00 -1,685,000.00 -1,225,000.00
Profit Loss From Continuing Operations -5,548,000.00 -23,197,000.00 -23,468,000.00
Profit Loss From Discontinued Operations 0.00 -46,000.00 -49,000.00
Profit (loss) -5,548,000.00 -23,243,000.00 -23,517,000.00
Profit Loss Attributable To Owners Of Parent -5,548,000.00 -23,255,000.00 -23,259,000.00
Profit Loss Attributable To Noncontrolling Interests 0.00 12.00 -258.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -5,548,000.00 -23,243,000.00 -23,517,000.00
Adjustments For Reconcile Profit Loss N/A 10,313,000.00 39,481,000.00 37,791,000.00
Adjustments For Finance Costs N/A 4,419,000.00 9,969,000.00 15,218,000.00
Adjustments For Decrease Increase In Inventories N/A -43,000.00 121,000.00 304,000.00
Adjustments For Depreciation And Amortisation Expense N/A 5,973,000.00 20,788,000.00 30,345,000.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss N/A 141,000.00 1,075,000.00 3,842,000.00
Adjustments For Provisions N/A 149,000.00 -1,065,000.00 -2,068,000.00
Adjustments For Fair Value Gains Losses N/A N/A 0.00 829,000.00
Other Adjustments To Reconcile Profit Loss N/A 152,000.00 10,457,000.00 -10,103,000.00
Adjustments For Reconcile Profit Loss N/A 10,313,000.00 39,481,000.00 37,791,000.00
Interest Paid Classified As Operating Activities N/A 2,494,000.00 9,969,000.00 15,218,000.00
Interest Received Classified As Operating Activities N/A 210,000.00 1,133,000.00 2,906,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 385,000.00 1,085,000.00 2,479,000.00
Other Inflows Outflows Of Cash Classified As Operating Activities N/A -2,669,000.00 -9,921,000.00 -14,791,000.00
Cash Flows From Used In Operating Activities N/A -1,395,000.00 4,694,000.00 -15,434,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 18,185,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 3,195,000.00 -4,223,000.00 -6,769,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 2,095,000.00 -4,344,000.00 -8,392,000.00
Cash Flows From Used In Investing Activities N/A -52,083,000.00 -2,449,000.00 -80,586,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 5,143,000.00 118,020,000.00 49,861,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 2,430,000.00 92,668,000.00 29,497,000.00
Cash Flows From Used In Financing Activities N/A 62,625,000.00 14,081,000.00 94,773,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 1,324,000.00 416,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 9,147,000.00 17,650,000.00 -831,000.00
Cash and cash equivalents 17,476,000.00 35,126,000.00 35,126,000.00 34,295,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 Spanish 🇪🇸
  • Consolidated Report 2020 - Q4 Spanish 🇪🇸

Capital Markets Information

ISIN

ES0105148003

LEI

959800HHEE9W4TZA8627

Sub-Industry

Biotechnology

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.